Trials / Completed
CompletedNCT03905148
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lifirafenib | RAF Dimer Inhibitor |
| DRUG | mirdametinib | MEK Inhibitor |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2024-10-09
- Completion
- 2025-10-23
- First posted
- 2019-04-05
- Last updated
- 2026-01-07
Locations
6 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03905148. Inclusion in this directory is not an endorsement.